Neurosoft Raises $7.5M for Advanced Brain-Computer Interfaces

Neurosoft Bioelectronics, a Swiss innovator in neural interfaces, has successfully closed a $7.5 million seed funding round. This capital infusion, led by Skybound Venture Capital with significant contributions from PL Capital, IAG Capital Partners, and Connecticut Innovations, will accelerate the development of its groundbreaking stretchable brain-computer interfaces. The company's technology aims to revolutionize neurological treatment by offering less invasive, surface-level brain interfaces that capture neural data with unprecedented clarity.

The core of Neurosoft's innovation lies in its highly compliant electrode technology, designed to conform to the brain's surface without penetrating delicate tissue. These soft interfaces are reportedly up to 1,000 times more flexible than existing materials and can cover approximately 30 times more cortical area. This capability is crucial in the competitive brain-computer interface (BCI) sector, where the quality and volume of neural data directly correlate with therapeutic and diagnostic potential. By minimizing tissue disruption, Neurosoft seeks to achieve superior signal acquisition for applications targeting conditions like epilepsy and severe tinnitus.

This latest funding brings Neurosoft's total capital raised to over $20 million, underscoring investor confidence in the burgeoning field of neurotechnology. The company, a spinout from Switzerland's EPFL, has already initiated clinical trials involving 10 patients at prominent institutions including UTHealth Houston in the United States and UMC Utrecht in the Netherlands. One such trial has utilized a 64-channel soft interface to aid in epilepsy surgery, demonstrating the technology's immediate clinical applicability.

Beyond its immediate medical applications, Neurosoft envisions its platform as the foundation for a novel neural data ecosystem. The company plans to develop a cortical foundation model, analogous to large language models, trained on extensive recordings of human brain activity. This ambitious goal positions Neurosoft at the forefront of AI-driven neuroscience, aiming to unlock deeper insights into brain function and pave the way for next-generation human-machine interactions. CEO and Co-Founder Nicolas Vachicouras, PhD, emphasized that their platform provides neural data at a quality and scale previously unattainable, essential for both improved patient outcomes and the advancement of cortical decoding.

The brain-computer interface market is experiencing significant growth, driven by advancements in AI and miniaturized electronics. While high-profile companies like Neuralink continue to push the boundaries of invasive BCI, Neurosoft's non-penetrative approach offers a compelling alternative. The company's strategic partnership with Science Corp, founded by former Neuralink president Max Hodak, further solidifies its position and is expected to expedite platform development. George Varvarelis, GP at Skybound Venture Capital, highlighted Neurosoft's engineering prowess and its potential to not only treat neurological disorders but also to gather critical data for mapping the human cortex.

With this new funding, Neurosoft Bioelectronics is set to advance its minimally invasive deployment in human patients and pursue commercialization of its initial product in the U.S. The company, headquartered in Geneva with a U.S. presence in New York, also holds over 25 patents related to its proprietary neural interface technology, signaling a strong intellectual property foundation for future growth.